RU2734236C2 - Композиции бендамустина и циклополисахарида - Google Patents
Композиции бендамустина и циклополисахарида Download PDFInfo
- Publication number
- RU2734236C2 RU2734236C2 RU2016124871A RU2016124871A RU2734236C2 RU 2734236 C2 RU2734236 C2 RU 2734236C2 RU 2016124871 A RU2016124871 A RU 2016124871A RU 2016124871 A RU2016124871 A RU 2016124871A RU 2734236 C2 RU2734236 C2 RU 2734236C2
- Authority
- RU
- Russia
- Prior art keywords
- bendamustine
- cyclodextrin
- beta
- composition
- cyclopolysaccharide
- Prior art date
Links
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 title claims abstract description 67
- 229960002707 bendamustine Drugs 0.000 title claims abstract description 66
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- 238000002347 injection Methods 0.000 claims abstract description 5
- 239000007924 injection Substances 0.000 claims abstract description 5
- 238000001802 infusion Methods 0.000 claims abstract description 3
- 229920000858 Cyclodextrin Polymers 0.000 claims description 35
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 22
- 239000001116 FEMA 4028 Substances 0.000 claims description 21
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical group OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 21
- 229960004853 betadex Drugs 0.000 claims description 21
- -1 beta-cyclodextrin sulfobutyl ester Chemical class 0.000 claims description 14
- 239000011734 sodium Substances 0.000 claims description 12
- 229910052708 sodium Inorganic materials 0.000 claims description 12
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 125000000129 anionic group Chemical group 0.000 claims description 4
- 230000000259 anti-tumor effect Effects 0.000 claims description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 3
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 17
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 229960001215 bendamustine hydrochloride Drugs 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 229940097362 cyclodextrins Drugs 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 150000001720 carbohydrates Chemical group 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 description 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 2
- PVPBHKCSQBLDEW-ZQOBQRRWSA-N (1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecol 4-hydroxybutane-1-sulfonic acid Chemical compound OCCCCS(O)(=O)=O.OC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@@H]6[C@@H](CO)O[C@H](O[C@@H]7[C@@H](CO)O[C@H](O[C@@H]8[C@@H](CO)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O PVPBHKCSQBLDEW-ZQOBQRRWSA-N 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- GOPKBPURTDZYDJ-FOUAGVGXSA-N chembl580490 Chemical compound NC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CN)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CN)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CN)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CN)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CN GOPKBPURTDZYDJ-FOUAGVGXSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20854109P | 2009-02-25 | 2009-02-25 | |
| US61/208,541 | 2009-02-25 | ||
| US26994409P | 2009-07-01 | 2009-07-01 | |
| US61/269,944 | 2009-07-01 | ||
| US27136409P | 2009-07-20 | 2009-07-20 | |
| US61/271,364 | 2009-07-20 | ||
| US27929309P | 2009-10-19 | 2009-10-19 | |
| US61/279,293 | 2009-10-19 | ||
| US12/711,979 US8436032B2 (en) | 2009-02-25 | 2010-02-24 | Bendamustine cyclopolysaccharide compositions |
| US12/711,979 | 2010-02-24 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011138844/15A Division RU2591804C2 (ru) | 2009-02-25 | 2010-02-24 | Композиции бендамустина и циклополисахарида |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016124871A RU2016124871A (ru) | 2018-12-04 |
| RU2016124871A3 RU2016124871A3 (enExample) | 2019-11-11 |
| RU2734236C2 true RU2734236C2 (ru) | 2020-10-13 |
Family
ID=42631521
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016124871A RU2734236C2 (ru) | 2009-02-25 | 2010-02-24 | Композиции бендамустина и циклополисахарида |
| RU2011138844/15A RU2591804C2 (ru) | 2009-02-25 | 2010-02-24 | Композиции бендамустина и циклополисахарида |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011138844/15A RU2591804C2 (ru) | 2009-02-25 | 2010-02-24 | Композиции бендамустина и циклополисахарида |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8436032B2 (enExample) |
| EP (2) | EP2400987B1 (enExample) |
| JP (1) | JP5654498B2 (enExample) |
| KR (1) | KR101798951B1 (enExample) |
| CN (2) | CN102421451B (enExample) |
| AU (1) | AU2010217297A1 (enExample) |
| CA (1) | CA2753641C (enExample) |
| ES (2) | ES2675620T3 (enExample) |
| HU (1) | HUE038234T2 (enExample) |
| NO (1) | NO2792369T3 (enExample) |
| RU (2) | RU2734236C2 (enExample) |
| WO (1) | WO2010097700A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2734236C2 (ru) | 2009-02-25 | 2020-10-13 | Софткемо Фарма Корп. | Композиции бендамустина и циклополисахарида |
| EP3158991B1 (en) * | 2010-01-28 | 2021-03-17 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
| WO2011103150A2 (en) * | 2010-02-18 | 2011-08-25 | Cephalon, Inc. | Lyophilized preparations of bendamustine |
| US20110207764A1 (en) * | 2010-02-23 | 2011-08-25 | Valery Alakhov | Cyclopolysaccharide compositions |
| US8383663B2 (en) | 2010-07-19 | 2013-02-26 | Supratek Pharma Inc. | Bendamustine anionic-catioinic cyclopolysaccharide compositions |
| EA028413B1 (ru) * | 2011-09-18 | 2017-11-30 | Эро-Селтик С.А. | Фармацевтические композиции |
| AR092790A1 (es) | 2012-02-01 | 2015-05-06 | Euro Celtique Sa | Derivados bencimidazolicos del acido hidroxamico |
| ES2718902T3 (es) | 2012-03-20 | 2019-07-05 | Eagle Pharmaceuticals Inc | Composición líquida destinada a ser utilizada en un método de tratamiento de condiciones en respuesta a la bendamustina en pacientes que requieren volúmenes reducidos para administración |
| HUE064884T2 (hu) | 2012-03-20 | 2024-04-28 | Eagle Pharmaceuticals Inc | Bendamusztin kiszerelések |
| US20230241218A1 (en) * | 2012-07-10 | 2023-08-03 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
| JP2016501876A (ja) * | 2012-11-30 | 2016-01-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ステロイドの抗痙攣活性 |
| CN109953954A (zh) * | 2013-08-27 | 2019-07-02 | V·沃道里斯 | 苯达莫司汀医药组合物 |
| GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| AU2016426574B2 (en) | 2016-10-11 | 2023-07-13 | Euro-Celtique S.A. | Hodgkin lymphoma therapy |
| GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
| GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
| GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
| GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
| US20200246312A1 (en) * | 2017-10-05 | 2020-08-06 | Tube Pharmaceuticals Gmbh | Oral bendamustine formulations |
| US11730815B2 (en) * | 2018-11-26 | 2023-08-22 | Good Health, Llc | Stable liquid pharmaceutical compositions comprising bendamustine |
| WO2020128913A1 (en) | 2018-12-18 | 2020-06-25 | Mundipharma International Corporation Limited | Compounds for treating multiple myeloma |
| CN111557904A (zh) * | 2020-04-09 | 2020-08-21 | 比卡生物科技（广州）有限公司 | 苯达莫司汀组合物及其用途 |
| EP4134068A4 (en) * | 2020-04-09 | 2024-02-07 | Bika Biotechnology (Guangzhou) Co., Ltd. | Bendamustine composition and use thereof |
| US20240148696A1 (en) | 2022-10-25 | 2024-05-09 | Softkemo Pharma Inc. | Lyophilized bendamustine-cyclodextrin composition |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD159289A1 (de) * | 1981-06-01 | 1983-03-02 | Uwe Olthoff | Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen |
| WO2006076620A2 (en) * | 2005-01-14 | 2006-07-20 | Cephalon, Inc. | Bendamustine pharmaceutical compositions for lyophilisation |
| US20070116729A1 (en) * | 2005-11-18 | 2007-05-24 | Palepu Nageswara R | Lyophilization process and products obtained thereby |
| RU2388462C2 (ru) * | 2003-12-31 | 2010-05-10 | Сайдекс, Инк. | Ингаляционная композиция, содержащая сульфоалкиловый эфир циклодекстрина и кортикостероид |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6407079B1 (en) | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
| US5068226A (en) * | 1987-12-07 | 1991-11-26 | Cyclex, Inc. | Pharmaceutical preparations containing cyclodextrins and their use in iontophoretic therapies |
| US5602112A (en) | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
| DK0814778T3 (da) * | 1995-03-10 | 2001-09-17 | Roche Diagnostics Gmbh | Polypeptidholdige farmaceutiske administrationsformer i form af mikropartikler og fremgangsmåde til fremstilling deraf |
| DE59607089D1 (de) * | 1995-03-10 | 2001-07-19 | Roche Diagnostics Gmbh | Polypeptid-enthaltende pharmazeutische darreichungsformen in form von mikropartikeln und verfahren zu deren herstellung |
| US6624141B1 (en) | 1999-03-17 | 2003-09-23 | The Regents Of The University Of Michigan | Protamine fragment compositions and methods of use |
| DE10204792A1 (de) * | 2002-02-06 | 2003-08-14 | Merck Patent Gmbh | Lyophilisierte Zubereitung enthaltend Immuncytokine |
| KR101121675B1 (ko) | 2002-04-19 | 2012-03-13 | 노파르티스 아게 | 신규 생체적합물질, 그의 제조방법 및 용도 |
| BR0317888A (pt) * | 2002-12-31 | 2005-12-06 | Altus Pharmaceuticals Inc | Cristais do hormÈnio do crescimento humano e processos para preparação dos mesmos |
| JP2007530654A (ja) * | 2004-03-30 | 2007-11-01 | ファイザー・プロダクツ・インク | シグナル伝達阻害剤の組合せ |
| MXPA06014215A (es) * | 2004-06-07 | 2007-05-04 | Nastech Pharm Co | Formulaciones intranasales de interferon beta libres de estabilizadores que son proteinas o polipeptidos. |
| AU2005268929A1 (en) * | 2004-08-03 | 2006-02-09 | Royal College Of Surgeons In Ireland | Phenytoin formulations, and uses thereof in wound healing |
| JP2008519032A (ja) * | 2004-11-03 | 2008-06-05 | キュラジェン コーポレイション | Ｆｇｆ−２０の調合物、生成方法および使用 |
| MX2007005361A (es) * | 2004-11-05 | 2008-01-11 | Cephalon Inc | Tratamientos para cancer. |
| US20060128653A1 (en) * | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of decitabine |
| UA94036C2 (ru) * | 2005-01-14 | 2011-04-11 | Сефалон, Инк. | Фармацевтическая композиция бендамустина, предназначенная для лиофилизации |
| US9295722B2 (en) * | 2005-01-28 | 2016-03-29 | The Scripps Research Institute | Bacterial glycolipid activation of CD1d-restricted NKT cells |
| CN1846685A (zh) | 2006-01-25 | 2006-10-18 | 济南帅华医药科技有限公司 | 含苯达莫司汀和其增效剂的缓释注射剂 |
| CN101646419A (zh) | 2006-11-08 | 2010-02-10 | 诺瓦瓦克斯股份有限公司 | 制备多相药物组合物的固体剂型的方法 |
| US8425459B2 (en) * | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
| US8372834B2 (en) * | 2007-03-02 | 2013-02-12 | University Of Wollongong | Compositions and methods for delivery of anti-cancer agents |
| CN101219113A (zh) | 2008-01-28 | 2008-07-16 | 济南帅华医药科技有限公司 | 含苯达莫司汀的复方抗癌缓释注射剂 |
| RU2734236C2 (ru) | 2009-02-25 | 2020-10-13 | Софткемо Фарма Корп. | Композиции бендамустина и циклополисахарида |
| CN101606934B (zh) * | 2009-07-27 | 2011-09-28 | 江苏奥赛康药业有限公司 | 盐酸苯达莫司汀组合物 |
-
2010
- 2010-02-24 RU RU2016124871A patent/RU2734236C2/ru not_active Application Discontinuation
- 2010-02-24 RU RU2011138844/15A patent/RU2591804C2/ru not_active Application Discontinuation
- 2010-02-24 CN CN2010800183017A patent/CN102421451B/zh active Active
- 2010-02-24 CA CA2753641A patent/CA2753641C/en active Active
- 2010-02-24 NO NO14177306A patent/NO2792369T3/no unknown
- 2010-02-24 ES ES14177306.9T patent/ES2675620T3/es active Active
- 2010-02-24 KR KR1020117022330A patent/KR101798951B1/ko active Active
- 2010-02-24 AU AU2010217297A patent/AU2010217297A1/en not_active Abandoned
- 2010-02-24 US US12/711,979 patent/US8436032B2/en active Active
- 2010-02-24 HU HUE14177306A patent/HUE038234T2/hu unknown
- 2010-02-24 ES ES10745872.1T patent/ES2525257T3/es active Active
- 2010-02-24 EP EP10745872.1A patent/EP2400987B1/en active Active
- 2010-02-24 JP JP2011550669A patent/JP5654498B2/ja active Active
- 2010-02-24 CN CN2012104076231A patent/CN102935080A/zh active Pending
- 2010-02-24 WO PCT/IB2010/000502 patent/WO2010097700A1/en not_active Ceased
- 2010-02-24 EP EP14177306.9A patent/EP2792369B1/en active Active
-
2013
- 2013-03-11 US US13/793,442 patent/US8703964B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD159289A1 (de) * | 1981-06-01 | 1983-03-02 | Uwe Olthoff | Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen |
| RU2388462C2 (ru) * | 2003-12-31 | 2010-05-10 | Сайдекс, Инк. | Ингаляционная композиция, содержащая сульфоалкиловый эфир циклодекстрина и кортикостероид |
| WO2006076620A2 (en) * | 2005-01-14 | 2006-07-20 | Cephalon, Inc. | Bendamustine pharmaceutical compositions for lyophilisation |
| US20070116729A1 (en) * | 2005-11-18 | 2007-05-24 | Palepu Nageswara R | Lyophilization process and products obtained thereby |
Non-Patent Citations (1)
| Title |
|---|
| R. Arun et al., Cyclodextrins as Drug Carrier Molecule: A Review, Sci Pharm. 2008; 76: 567-598. * |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2675620T3 (es) | 2018-07-11 |
| WO2010097700A1 (en) | 2010-09-02 |
| EP2400987B1 (en) | 2014-09-03 |
| JP5654498B2 (ja) | 2015-01-14 |
| RU2591804C2 (ru) | 2016-07-20 |
| JP2012519657A (ja) | 2012-08-30 |
| AU2010217297A1 (en) | 2011-10-20 |
| NO2792369T3 (enExample) | 2018-09-15 |
| US8703964B2 (en) | 2014-04-22 |
| KR101798951B1 (ko) | 2017-11-20 |
| EP2400987A1 (en) | 2012-01-04 |
| US20130190372A1 (en) | 2013-07-25 |
| RU2011138844A (ru) | 2013-04-10 |
| ES2525257T3 (es) | 2014-12-19 |
| CA2753641C (en) | 2014-09-16 |
| CN102421451A (zh) | 2012-04-18 |
| EP2792369B1 (en) | 2018-04-18 |
| HUE038234T2 (hu) | 2018-10-29 |
| RU2016124871A3 (enExample) | 2019-11-11 |
| US20100216858A1 (en) | 2010-08-26 |
| EP2400987A4 (en) | 2012-08-22 |
| EP2792369A1 (en) | 2014-10-22 |
| CA2753641A1 (en) | 2010-09-02 |
| RU2016124871A (ru) | 2018-12-04 |
| KR20120015294A (ko) | 2012-02-21 |
| US8436032B2 (en) | 2013-05-07 |
| CN102421451B (zh) | 2013-11-06 |
| CN102935080A (zh) | 2013-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2734236C2 (ru) | Композиции бендамустина и циклополисахарида | |
| WO2007095850A1 (en) | A pharmaceutical composition of docetaxel, preparation and use | |
| AU2019219792B2 (en) | Bendamustine anionic-cationic cyclopolysaccharide compositions | |
| KR20090084925A (ko) | 피모벤단과 사이클로덱스트린의 복합물을 포함하는 액상 제제 | |
| WO2018233095A1 (zh) | 具有淋巴靶向功能的生物自组装纳米晶注射剂及制备方法 | |
| AU2013377404B2 (en) | Composition of cabazitaxel and sulfobutylether beta-cyclodextrin | |
| CN105769821A (zh) | 他克莫司自组装聚合物纳米粒给药系统及其制备方法 | |
| CN101590029B (zh) | 一种丙泊酚组合物 | |
| CN113616620A (zh) | 安罗替尼白蛋白纳米颗粒及其制备方法和用途、及包含其的制剂 | |
| CN102716095B (zh) | 一种紫杉醇囊泡型磷脂凝胶注射剂 | |
| CN103040745B (zh) | 一种环磷腺苷葡胺脂质体注射剂 | |
| CN112451475B (zh) | 一种用于治疗空洞型肺结核的长效缓释凝胶 | |
| HK1168556A (en) | Bendamustine cyclopolysaccharide compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20190624 |
|
| FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20190813 |